Clinical Trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases
Trial Details
NCT Number NCT07161193
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Collaborators: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China
Conditions Autoimmune Diseases
Enrollment 30 participants
Start Date 2025-09-30
Primary Completion 2027-08-18 (estimated)
Study Completion 2027-11-18 (estimated)
Updated on ClinicalTrials.gov 2025-09-08